Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>Cirata reported Q125 Trading update for the 3 months to March 2025; its services accelerate datadriven revenue growth by automating data transfer and integration to modern cloud analytics and AI platforms without downtime or disruption.</li>
<li>Revenue of $3m represents the strongest quarter since Q1 2019 and a 330% increase compared to Q124 driven by an enterprise-wide Digital Integration (DI) contract with a leading UK retailer and DI being the core growth driver.</li>
<li>The business mix continued to improve with DI accounting for 80% of bookings and DevOps software the remaining (Q124 DI 57%: DevOps 43%). </li>
</ul>


Cirata reported Q125 Trading update for the 3 months to March 2025; its services accelerate datadriven revenue growth by automating data transfer and integration to modern cloud analytics and AI platforms without downtime or disruption.
Revenue of $3m represents the strongest quarter since Q1 2019 and a 330% increase compared to Q124 driven by an enterprise-wide Digital Integration (DI) contract with a leading UK retailer and DI being the core growth driver.
The business mix continued to improve with DI accounting for 80% of bookings and DevOps software the remaining (Q124 DI 57%: DevOps 43%). 


<ul>
<li>The UK drug delivery company focused on the localised delivery of chemotherapy drugs, announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer.</li>
<li>The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the AIM market last year and which highlighted the potential of ChemoSeed in multiple disease areas.</li>
<li>The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. </li>
</ul>


The UK drug delivery company focused on the localised delivery of chemotherapy drugs, announced that it has been awarded a grant by Innovate UK to support the pre-clinical development of the Company's proprietary ChemoSeed technology in prostate cancer.
The Project is in line with the Company's strategy as detailed in the admission document published when CRISM joined the AIM market last year and which highlighted the potential of ChemoSeed in multiple disease areas.
The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'. 


United Kingdom

DP Poland Plc, through its subsidiary, DP Polska SA, develops and operates Domino?s Pizza stores under master franchise agreement in Poland. It also sub-franchises the right to develop and operate Domino?s Pizza stores. The company operates eight corporately managed Domino?s stores and eight sub-franchised stores in Warsaw; and four corporately managed stores in Krakow, two in Wroclaw, one in Gdansk, and one in Szczecin. DP Poland Plc is headquartered in Warsaw, Poland.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

DP Poland PLC (DPP LN)

Hybridan Small Cap Feast: 16/04/2025

The business mix continued to improve with DI accounting for 80% of bookings and DevOps software the remaining (Q124 DI 57%: DevOps 43%).

Hybridan

Hybridan Small Cap Feast: 27/03/2025

The Innovate UK grant was awarded as part of the Government's 'Launchpad: life and health sciences, Northern Ireland - Rd2 MFA'.

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)